Found this on another board and thought I'd post.

- First NDA submission anticipated by year's end for ANX-530

- Oncologist preference for ANX-530 pricing at 10x that of generic

ANX-530:
- $100m+ U.S. market opportunity
- Growing demand despite lack of promotion
- ANX-530 patent will extend through 2025

ANX-514
- $1bln+ U.S. market opportunity
- Opportunity to pre-empt generic equivalent by 3.5 years
- ANX-514 patent will extend through 2027

Financial overview:
-Cash/equivalents of $5.4 million
-NO Debt
-12 months cash-on-hand

2009 Milestones:
-Restructured operations to minimize costs (check)
-Completed ANX-514 pharmcokinetic study (check)
-Secured funding to support operations (check)
-Commercial manufacturing scale up of ANX-530 (check)
-Complete ANX-514 data analysis
-Request FDA review meeting for ANX-514
-Submit ANX-530 NDA

Investment Summary:
-Large market opportunities accessible with affordable, share-shifting commercial plan
-Developing 2 products for established markets with first NDA submission in 2009
-Scalable long term business model.